Nyrada (ASX: NYR) has announced a dual development and IP success for its Xolatryp oncology program, demonstrating enhanced anti-tumour efficacy in preclinical models and securing a US patent allowance.
In a liver cancer xenograft model, Xolatryp combined with doxorubicin reduced tumour volume by 57% versus vehicle control at Day 14.
This compared to 41% for doxorubicin alone, with the combination therapy achieving the earliest statistically significant tumour reduction at Day 4 and delivering an approximate 39% improvement in anti-tumour activity over doxorubicin monotherapy.
Xolatryp monotherapy reduced tumour volume by 32% at Day 14, with significant reductions observed from Day 10.
While two premature deaths occurred in the combination group, consistent with tumour lysis syndrome, a favourable trend in plasma cardiac troponin I was observed for animals receiving Xolatryp.
US Patent Allowance for Xolatryp
The US Patent and Trademark Office has issued a notice of allowance for a patent application covering the composition of matter of Xolatryp.
If granted, this patent will provide US intellectual property protection over Xolatryp's chemical structure for 20 yearsfrom the September 2024 filing date.
This builds on a broader global patent portfolio, including filings in Australia, Europe, and Japan.
Composition-of-matter protection is intended to prevent unauthorised manufacture, use, sale, or import of Xolatrypwithout Nyrada's approval.
A provisional patent application for Xolatryp as an anti-cancer agent has also been lodged.
Ongoing Development
Nyrada's Quarterly Activities Report from April 2026 indicated preclinical oncology studies were initiated.
These studies explore Xolatryp's efficacy across oncology indications, including its cardioprotection potential against doxorubicin-induced cardiotoxicity.
The company's lead program involves a Phase IIa clinical trial for Xolatryp in heart attack patients, with recruitment commencing in April 2026.
Nyrada reported AU$6.74 million in cash and cash equivalents as of 31 March 2026, providing an estimated funding runway of over seven quarters.
Balanced Outlook
Nyrada has advanced its Xolatryp program with positive preclinical oncology data and a significant US patent allowance, potentially bolstering its intellectual property and future commercialisation.
However, the path forward, particularly in oncology, remains preclinical.
Ongoing clinical development will focus on the company's lead cardiovascular indication, and investors need to monitor upcoming efficacy and safety data alongside cash burn.
